Amarin Corp. PLC (NASDAQ:AMRN) saw unusually-strong trading volume on Tuesday . Approximately 8,545,891 shares changed hands during trading, an increase of 262% from the previous session’s volume of 2,363,877 shares.The stock last traded at $3.13 and had previously closed at $2.91.

Several analysts have weighed in on AMRN shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Amarin Corp. PLC in a research report on Monday, May 9th. Jefferies Group reissued a “buy” rating on shares of Amarin Corp. PLC in a research report on Wednesday, June 8th. Finally, Zacks Investment Research raised shares of Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th.

The firm’s market capitalization is $586.52 million. The company’s 50 day moving average is $2.26 and its 200 day moving average is $1.80.

Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.03. The company earned $25.30 million during the quarter, compared to analysts’ expectations of $26.77 million. The company’s quarterly revenue was up 60.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.16) EPS. On average, equities analysts predict that Amarin Corp. PLC will post ($0.49) earnings per share for the current year.

An institutional investor recently raised its position in Amarin Corp. PLC stock. OppenheimerFunds Inc. raised its position in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned approximately 2.90% of Amarin Corp. PLC worth $10,061,000 at the end of the most recent quarter.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.